康哲药业：创新药CMS-D017临床试验获批准

财中社07-15

　　7月15日，康哲药业（00867）发布公告，自主研发的创新药补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。

　　该产品旨在治疗年龄相关性黄斑变性（AMD），NMPA同意开展临床试验以评估其安全性和有效性。

　　CMS-D017是一种新型口服选择性补体因子B小分子抑制剂，能够阻止补体旁路途径的异常活化，从而减低对靶组织和器官的损伤，缓解AMD等补体失调相关疾病进展。CMS-D017临床试验的获批，将提升公司在眼科领域的整体竞争力，并与现有产品形成协同效应。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651457047?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651457047","market":"sh","top_or_hot":-1,"title":"康哲药业：创新药CMS-D017临床试验获批准","media":"财中社","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.00867&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　7月15日，<span><a href=\"https://laohu8.com/S/00867\">康哲药业</a></span>（00867）发布公告，自主研发的<span>创新药</span><span></span>补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。</p><p>　　该产品旨在治疗年龄相关性黄斑变性（<a href=\"https://laohu8.com/S/AMD\">AMD</a>），NMPA同意开展临床试验以评估其安全性和有效性。</p><p>　　CMS-D017是一种新型口服选择性补体因子B小分子抑制剂，能够阻止补体旁路途径的异常活化，从而减低对靶组织和器官的损伤，缓解AMD等补体失调相关疾病进展。CMS-D017临床试验的获批，将提升公司在眼科领域的整体竞争力，并与现有产品形成协同效应。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业：创新药CMS-D017临床试验获批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业：创新药CMS-D017临床试验获批准\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.00867&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　7月15日，<span><a href=\"https://laohu8.com/S/00867\">康哲药业</a></span>（00867）发布公告，自主研发的<span>创新药</span><span></span>补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。</p><p>　　该产品旨在治疗年龄相关性黄斑变性（<a href=\"https://laohu8.com/S/AMD\">AMD</a>），NMPA同意开展临床试验以评估其安全性和有效性。</p><p>　　CMS-D017是一种新型口服选择性补体因子B小分子抑制剂，能够阻止补体旁路途径的异常活化，从而减低对靶组织和器官的损伤，缓解AMD等补体失调相关疾病进展。CMS-D017临床试验的获批，将提升公司在眼科领域的整体竞争力，并与现有产品形成协同效应。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202607153807630490.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607153807630490.html","article_id":"2651457047","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651457047","pubTimestamp":1784114220,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月15日，康哲药业（00867）发布公告，自主研发的创新药补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。该产品旨在治疗年龄相关性黄斑变性（AMD），NMPA同意开展临床试验以评估其安全性和有效性。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BMED":"iShares Health Innovation Active ETF","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","CMS":"CMS能源","BK1191":"制药","00867":"康哲药业","BK1161":"生物科技","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","BK1593":"医美概念股","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","BK4208":"复合型公用事业","MEDX":"HORIZON KINETICS MEDICAL ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK1574":"生物医药B类股","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU2500361329.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"B\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","BK4588":"碎股","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","06978":"永泰生物-B"},"translate_title":"Kangzhe Pharmaceutical: Clinical trial of innovative drug CMS-D017 approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"CMS":1.5,"06978":1.5,"IBBQ":1.5,"BMED":1.5,"MEDX":1.5,"00867":1.5},"content_text":"7月15日，康哲药业（00867）发布公告，自主研发的创新药补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。　　该产品旨在治疗年龄相关性黄斑变性（AMD），NMPA同意开展临床试验以评估其安全性和有效性。　　CMS-D017是一种新型口服选择性补体因子B小分子抑制剂，能够阻止补体旁路途径的异常活化，从而减低对靶组织和器官的损伤，缓解AMD等补体失调相关疾病进展。CMS-D017临床试验的获批，将提升公司在眼科领域的整体竞争力，并与现有产品形成协同效应。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651457047","isCrawlerRequest":true}